Palisade Bio, Inc. (NASDAQ:PALI) Short Interest Update

Palisade Bio, Inc. (NASDAQ:PALI) was the target of a large decline in short interest during the month of January. As of January 15th, there was short interest totalling 66,300 shares, a decline of 96.4% from the December 31st total of 1,840,000 shares. Based on an average daily trading volume, of 1,270,000 shares, the days-to-cover ratio is currently 0.1 days. Currently, 2.4% of the shares of the stock are short sold.

Hedge Funds Weigh In On Palisade Bio

An institutional investor recently bought a new position in Palisade Bio stock. JPMorgan Chase & Co. purchased a new position in shares of Palisade Bio, Inc. (NASDAQ:PALI) during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm purchased 8,200 shares of the company’s stock, valued at approximately $29,000. JPMorgan Chase & Co. owned 0.54% of Palisade Bio as of its most recent SEC filing. Institutional investors own 11.79% of the company’s stock.

Wall Street Analyst Weigh In

PALI has been the topic of several research reports. Brookline Capital Management started coverage on shares of Palisade Bio in a research report on Wednesday, November 20th. They issued a “buy” rating and a $38.00 price target on the stock. Maxim Group lowered their target price on Palisade Bio from $22.50 to $8.00 and set a “buy” rating on the stock in a report on Wednesday, November 13th.

Palisade Bio Price Performance

Shares of PALI stock opened at $1.43 on Thursday. The firm has a 50-day moving average price of $1.86 and a 200 day moving average price of $2.93. Palisade Bio has a twelve month low of $1.33 and a twelve month high of $11.75.

Palisade Bio (NASDAQ:PALI) last released its earnings results on Tuesday, November 12th. The company reported ($2.32) EPS for the quarter, topping the consensus estimate of ($3.35) by $1.03. Equities analysts predict that Palisade Bio will post -12.43 earnings per share for the current year.

About Palisade Bio

Palisade Bio, Inc, a clinical-stage biopharmaceutical company, focuses on focuses on developing therapeutics that protect the integrity of the intestinal barrier in the United States. The company's lead therapeutic candidate is PALI-2108, a prodrug PDE4 inhibitor, currently under pre-clinical development as a therapeutic for patients living with inflammatory bowel diseases, including ulcerative colitis and Crohn's disease (CD), as well as develops PALI-1908, an oral, selective PDE4 inhibitor prodrug that is locally bioactivated in the terminal ileum of CD patients, currently in the research stage.